These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. Madelain V; Duthey A; Mentré F; Jacquot F; Solas C; Lacarelle B; Vallvé A; Barron S; Barrot L; Mundweiler S; Thomas D; Carbonnelle C; Raoul H; de Lamballerie X; Guedj J Antiviral Res; 2020 May; 177():104758. PubMed ID: 32135218 [TBL] [Abstract][Full Text] [Related]
9. Coadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and disease. Westover JB; Bailey KW; Wasson SR; Boardman KM; Lustig KH; Amberg SM; Gowen BB Antiviral Res; 2024 Sep; 229():105952. PubMed ID: 38945484 [TBL] [Abstract][Full Text] [Related]
10. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. Mendenhall M; Russell A; Smee DF; Hall JO; Skirpstunas R; Furuta Y; Gowen BB PLoS Negl Trop Dis; 2011 Oct; 5(10):e1342. PubMed ID: 22022624 [TBL] [Abstract][Full Text] [Related]
11. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Gowen BB; Westover JB; Sefing EJ; Van Wettere AJ; Bailey KW; Wandersee L; Komeno T; Furuta Y Antiviral Res; 2017 Sep; 145():131-135. PubMed ID: 28780425 [TBL] [Abstract][Full Text] [Related]
12. Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections. Okogbenin S; Erameh C; Okoeguale J; Edeawe O; Ekuaze E; Iraoyah K; Agho J; Groger M; Kreuels B; Oestereich L; Babatunde FO; Akhideno P; Günther S; Ramharter M; Omansen T Emerg Infect Dis; 2022 Oct; 28(10):2060-2063. PubMed ID: 36148915 [TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. Asogun DA; Adomeh DI; Ehimuan J; Odia I; Hass M; Gabriel M; Olschläger S; Becker-Ziaja B; Folarin O; Phelan E; Ehiane PE; Ifeh VE; Uyigue EA; Oladapo YT; Muoebonam EB; Osunde O; Dongo A; Okokhere PO; Okogbenin SA; Momoh M; Alikah SO; Akhuemokhan OC; Imomeh P; Odike MA; Gire S; Andersen K; Sabeti PC; Happi CT; Akpede GO; Günther S PLoS Negl Trop Dis; 2012; 6(9):e1839. PubMed ID: 23029594 [TBL] [Abstract][Full Text] [Related]
14. Monitoring of Lassa virus infection in suspected and confirmed cases in Ondo State, Nigeria. Salu OB; Amoo OS; Shaibu JO; Abejegah C; Ayodeji O; Musa AZ; Idigbe I; Ezechi OC; Audu RA; Salako BL; Omilabu SA Pan Afr Med J; 2020; 36():253. PubMed ID: 33014249 [TBL] [Abstract][Full Text] [Related]
15. Favipiravir: a new medication for the Ebola virus disease pandemic. Nagata T; Lefor AK; Hasegawa M; Ishii M Disaster Med Public Health Prep; 2015 Feb; 9(1):79-81. PubMed ID: 25544306 [TBL] [Abstract][Full Text] [Related]
16. Lassa fever - full recovery without ribavarin treatment: a case report. Ajayi NA; Ukwaja KN; Ifebunandu NA; Nnabu R; Onwe FI; Asogun DA Afr Health Sci; 2014 Dec; 14(4):1074-7. PubMed ID: 25834520 [TBL] [Abstract][Full Text] [Related]
17. Lassa fever. Effective therapy with ribavirin. McCormick JB; King IJ; Webb PA; Scribner CL; Craven RB; Johnson KM; Elliott LH; Belmont-Williams R N Engl J Med; 1986 Jan; 314(1):20-6. PubMed ID: 3940312 [TBL] [Abstract][Full Text] [Related]
19. [A man with fatal Lassa fever following a stay in Sierra Leone]. Veldkamp PJ; Schippers EF Ned Tijdschr Geneeskd; 2002 Nov; 146(46):2201-4. PubMed ID: 12467165 [TBL] [Abstract][Full Text] [Related]